Prolacta Bioscience Opens An Expanded Facility In Industry, California
10/17/2013
The freezer at the new facility stands at 115,560 square foot, which will provide controlled frozen storage capacity for more than 110,000 liters of breast milk. The complex also includes two ISO 8 and one ISO 7 clean rooms totaling over 10,000 square feet.
Prolacta CEO Scott Elster said,"We now have a facility that can provide human milk nutritional products for every Neonatal Intensive Care Unit in the U.S. As hospitals continue to transition to exclusive human milk diets in their NICU, we are positioned to meet their needs by providing fortifier, pasteurized milk, and ready-to-feed products, all free of any cow milk or cow milk proteins.”
"Prolacta stands alone in being able to provide NICUs with a complete line of human milk formulations to meet the needs of critically ill premature infants," Elster added. "We are proud to be the first and only company to make human milk nutritional products that will be of such a significant benefit for premature infants."
Project Announcements
NSP Panels Establishes Mullins, South Carolina, Manufacturing Operations
03/25/2026
United Composite Materials Plans Greenville County, South Carolina, Manufacturing Operations
03/25/2026
Van-Am Expands St. Joseph, Missouri, Operations
03/25/2026
Lufburrow & Company Plans Aberdeen, Maryland, Manufacturing Operations
03/24/2026
Autokiniton Expands Bellevue, Ohio, Manufacturing Operations
03/24/2026
Philip Morris International Plans Tampa, Florida, Operations
03/24/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
The Geography of Packaging: Why Location Strategy Matters More Than Ever
Q1 2026